bevacizumab

An angiogenesis inhibitor called bevacizumab (Avastin) was approved by the U.S. Food and Drug Administration in 2004 for the treatment of metastatic colorectal cancer. Bevacizumab works by binding to and inhibiting the action of vascular endothelial growth factor (VEGF), which normally stimulates angiogenesis. However, bevacizumab is not effective when…

An angiogenesis inhibitor called bevacizumab (Avastin) was approved by the U.S. Food and Drug Administration in 2004 for the treatment of metastatic colorectal cancer. Bevacizumab works by binding to and inhibiting the action of vascular endothelial growth factor (VEGF), which normally stimulates angiogenesis. However, bevacizumab is not effective when…

…agents, such as interferon or bevacizumab (Avastin; a monoclonal antibody), following surgery. Stage III melanoma has spread to nearby lymph nodes, and surgical removal of the cancerous nodes is required. This may be followed by biological therapy or chemotherapy. Stage IV melanoma has spread beyond the regional lymph nodes to…